Literature DB >> 23124683

Internal validation of models with several interventions.

Afschin Gandjour1, Amiram Gafni.   

Abstract

In cost-effectiveness analyses, models are used typically to synthesize the best available data and/or extrapolate beyond clinical trial data. Ideally, models should be validated both internally and externally. The purpose of this paper is to suggest a test for internal validation of models where several interventions for the same clinical indication are compared. To the best of our knowledge, such a specific test does not yet exist. There are four versions of the test, which consider the relationship between incremental downstream costs and effects in the case of a single or several endpoints. We apply two versions of the validation test to published cost-effectiveness analyses of physical activity programs and demonstrate internal validity of the model in one study and lack of internal validity of the model in the other study.

Mesh:

Year:  2012        PMID: 23124683     DOI: 10.1007/s10198-012-0434-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  19 in total

Review 1.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Authors:  Z Philips; L Ginnelly; M Sculpher; K Claxton; S Golder; R Riemsma; N Woolacoot; J Glanville
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014

2.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

Review 3.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

4.  Adjusting life for quality or disability: stylistic difference or substantial dispute?

Authors:  Mara Airoldi; Alec Morton
Journal:  Health Econ       Date:  2009-11       Impact factor: 3.046

5.  Cost effectiveness of community-based physical activity interventions.

Authors:  Larissa Roux; Michael Pratt; Tammy O Tengs; Michelle M Yore; Teri L Yanagawa; Jill Van Den Bos; Candace Rutt; Ross C Brownson; Kenneth E Powell; Gregory Heath; Harold W Kohl; Steven Teutsch; John Cawley; I-Min Lee; Linda West; David M Buchner
Journal:  Am J Prev Med       Date:  2008-12       Impact factor: 5.043

6.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

7.  Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.

Authors:  B O'Brien; M Levine; A Willan; R Goeree; S Haley; G Blackhouse; M Gent
Journal:  Arch Intern Med       Date:  1999-10-25

8.  The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

Authors:  William H Herman; Thomas J Hoerger; Michael Brandle; Katherine Hicks; Stephen Sorensen; Ping Zhang; Richard F Hamman; Ronald T Ackermann; Michael M Engelgau; Robert E Ratner
Journal:  Ann Intern Med       Date:  2005-03-01       Impact factor: 25.391

9.  Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions.

Authors:  S D Pinkerton; D R Holtgrave; W DiFranceisco; S Semaan; S L Coyle; A P Johnson-Masotti
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

10.  Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study.

Authors:  P P Sendi; B A Craig; D Pfluger; A Gafni; H C Bucher
Journal:  J Eval Clin Pract       Date:  1999-08       Impact factor: 2.431

View more
  2 in total

1.  Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study.

Authors:  Renee Lévesque; Daniele Marcelli; Héloïse Cardinal; Marie-Line Caron; Muriel P C Grooteman; Michiel L Bots; Peter J Blankestijn; Menso J Nubé; Aileen Grassmann; Bernard Canaud; Afschin Gandjour
Journal:  Appl Health Econ Health Policy       Date:  2015-12       Impact factor: 2.561

2.  The price of curing cancer.

Authors:  Afschin Gandjour
Journal:  BMC Health Serv Res       Date:  2021-12-11       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.